Company / Total Assets
Allogene Therapeutics, Inc. Total Assets History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$415.9M
FY2025
5-year range
$415.9M / $1.0B
FY2021-FY2025
Trend
-24.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Assets has declined for 4 consecutive years, from $1.0B in FY2021 to $416M in FY2025.
Based on SEC 10-K filings.
$416M in FY2025 with a 3-year CAGR of -24.8%.
Declined from $643M to $416M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- -24.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Allogene Therapeutics, Inc.'s total assets has declined for 4 consecutive years.
- 3-year CAGR of -24.8%, indicating a declining trend.
- In FY2025, total assets decreased 24.2% year-over-year.
- Peak total assets was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $415.9M | -24.2% |
| FY2024 | $548.7M | -14.6% |
| FY2023 | $642.8M | -34.3% |
| FY2022 | $978.1M | -5.8% |
| FY2021 | $1.0B | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026